摘要目的 观察BACOD方案治疗复发及难治性非霍奇金淋巴瘤(NHL)的疗效及患者不良反应.方法 65例复发及难治性NHL患者,采用BACOD方案进行化疗,具体为:博莱霉素10mg/m2,静脉滴注,第2、9天;环磷酰胺750 mg/m2,静脉滴注,第1天;长春地辛3 mg/m2,静脉注射,第1、8天;阿糖胞苷150 mg/m2,静脉滴注,第2天至第5天;地塞米松10 mg/m2,静脉滴注,第1天至第7天,3周为1个疗程.结果 完全缓解18例,部分缓解30例,稳定13例,进展4例,有效率70.8%.有效患者中位缓解时间10个月(2～35个月).1年生存率32.3%,2年生存率24.6%.患者主要不良反应为骨髓抑制.结论 BACOD方案可作为复发及难治性NHL的解救方案.

abstractsObjective To investigate the efficacy and adverse events of BACOD regimen for relapsed and refractory non-Hodgkin lymphoma (NHL). Methods Sixty patients with relapsed and refractory NHL received chemotherapy of BACOD regimen: bleomycin 10 mg/m2, intravenous drip on the 2nd and 9th day;cyclophosphamide 750 mg/m2, intravenous drip on 1st day; vindesine 3 mg/m2, intravenous drip on 1st and 8th day; cytarabine 150 mg/m2, intravenous drip on 2nd-5th days; dexamethasone 10 mg/m2, intravenous drip on 2nd-5th days; every 3 weeks was one cycle. Results Eighteen cases (27.7 %) received the complete remission (CR), 30 the partial remission (PR), 13 stable disease (SD) and 4 progressive disease (PD). The overall response (CR+PR) rate was 70.8 %. The median remission time of patients with response was 11 months(2-38 months). The 1-year survival rate was 32.3 % and the 2-year survival rate was 24.6 %. The main adverse events were myelosuppression. Conclusion BACOD regimen can be used as the relief regimen of relapsed and refractory NHL.